ARN-75039 / Arisan Therap - LARVOL DELTA

ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov) - P2 | N=135 | Suspended | Sponsor: Arisan Therapeutics, Inc. | Active, not recruiting ➔ Suspended

Trial suspension • Infectious Disease

ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov) - P2 | N=135 | Active, not recruiting | Sponsor: Arisan Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

The virus entry inhibitor ARN-75039 provides therapeutic protection against Lassa virus infection in guinea pigs. (PubMed, Sci Transl Med) - "There are no vaccines available for prevention of Lassa fever, and the primary therapeutic for treatment (ribavirin) has questionable antiviral activity and no formal approval for use. ARN-75039-treated animals exhibited minimal disease signs and undetectable viremia. These results suggest that ARN-75039, for which a phase 1 human clinical trial has now been completed, may offer robust protection against LASV infection."

Journal • Infectious Disease

ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov) - P2 | N=135 | Recruiting | Sponsor: Arisan Therapeutics, Inc.

New P2 trial • Infectious Disease

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (clinicaltrials.gov) - P2/3 | N=1755 | Recruiting | Sponsor: Irrua Specialist Teaching Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

pH-induced conformational changes and inhibition of the Lassa virus spike complex. (PubMed, Cell Host Microbe) - "Using the entry inhibitor ARN-75039, we validate our findings and establish the molecular basis for the binding and function of this investigational drug. These data define the molecular basis for the cell entry of LASV and will promote efforts in combating this virus and potentially related viral pathogens."

Journal • LAMP1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=94 | Completed | Sponsor: Arisan Therapeutics, Inc. | Recruiting ➔ Completed | N=64 ➔ 94 | Trial completion date: Jun 2025 ➔ Mar 2025

Enrollment change • Trial completion • Trial completion date • Infectious Disease

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Arisan Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Infectious Disease

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Arisan Therapeutics, Inc.

New P1 trial • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc. | Suspended ➔ Recruiting

Enrollment open • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Suspended | Sponsor: Arisan Therapeutics, Inc. | Trial completion date: Oct 2023 ➔ Apr 2025 | Recruiting ➔ Suspended | Trial primary completion date: Jul 2023 ➔ Jan 2025

Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc.

New P1 trial • Infectious Disease